Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

23 Apr 2009 08:55

RNS Number : 0351R
ViaLogy PLC
23 April 2009
 



ViaLogy 

VIALOGY ACHIEVES ANOTHER OIL WELL SUCCESS 

LondonApril, 23, 2009. Vialogy (LSE: VIY) announces another successful well in the Galba Prospect in South Central Texas. This well success reinforces operational and commercial validation of the company's QuantumRD™ software-based seismic interpretation service for oil and gas reservoir discovery and characterization. ViaLogy accurately predicted the size, location and formation porosity for this prospect. 

The new producing well, called Mary Ridgeway #1, is located on the Galba lease owned by ViaLogy's partner Atascosa Exploration LLC of San Antonio. The Mary Ridgeway#1 well is estimated to hold larger recoverable reserves compared to ViaLogy's previously announced Cindy Bartlett#2 well discovery announced in March 2009. As before, Vialogy predicted the subsurface hydrocarbon reservoir boundaries, the porosity of the oil-bearing Bartosh sands, formation depth, and positioned the well. Prospect estimates were confirmed by the well-logging and independent subsequent core laboratory analysis. The companies will be releasing actual figures over the next few days, including dollar estimates of recoverable reserves. As announced earlier, under its current contract with Atascosa, Vialogy will receive 5% Back-In-After-Payout working interest in the well. 

As in the previous successful oil find in March, Vialogy's proprietary QuantumRD served as the analytical tool for assessing 3D seismic data sets. The technology exploits subtle variations in seismic noise to overcome limitations in current processing and interpretation techniques, making possible a more accurate analysis of seismic data now in widespread use in the industry. 

Vialogy now turns its attention to its next contracted Atascosa well project, with drilling expected to begin before the end of Q2 2009, and, equally as important, to business opportunities with new customers. Interest in the technology appears considerable. 

Vialogy CEO, Robert W. Dean, said, "This successful well marks a major step forward for the company in demonstrating the capability of QuantumRD and its relevance in the oil patch. Our hope and intention is to enable multiple producing wells in the coming months, cautioning at the same time that no seismic interpretation technique can be one hundred percent effective one hundred percent of the time. What we can bring to the industry over time is a major improvement in the ratio of drilling dry holes to producing wells, and thus considerable cost savings." 

For further information please contact: 

ViaLogy  Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)  Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC  John D. Mullins, CEO (+1 210-402-3656)  Nominated Advisor (Seymour Pierce)  Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC  St. Helen's Capital +44 (0) 7628 5582 

About ViaLogy: Network Centric Signal Processing  ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geosiesmology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPUUUACUPBUMW
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.